Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non Small Cell Lung Cancer, and Other Solid Tumors.
UNLABELLED We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin dependent kinases (CDK) 4 and 6, in a multicenter study including phase I dose escalation followed by tumor specific cohorts for breast cancer, non small cell lung cancer (NSCLC) glioblastoma, melanoma, and colorectal cancer. A total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor specific cohorts. Dose limiting toxicity was grade 3 fatigue. The maximum tolerated dose was 200 mg every 12 hours. The most common possibly related treatment emergent adverse events involved fatigue and the gastrointestinal, renal, or hematopoietic systems. Plasma concentrations increased with dose, and pharmacodynamic effects were observed in proliferating keratinocytes and tumors. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. For hormone receptor positive breast cancer, the overall response rate was 31% moreover, 61% of patients achieved either response or stable disease lasting =6 months. SIGNIFICANCE Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition. This first in human experience demonstrates single agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors. Cancer Discov; 6(7) 740 53. (c)2016 AACR.See related commentary by Lim et al. p. 697This article is highlighted in the In This Issue feature, p. 681.
Cancer discovery